Nano-silymarin combined with methylene blue photodynamic therapy versus monotherapies of head and neck squamous cell carcinoma: in-vitro study. (2026)

Peer-Reviewed Study · Hefzi D, Koopaie M, Hakimiha N, Younespour S · June 29, 2026

Hefzi D et al., 2026-06-29: Iranian 2026 in-vitro study testing nano-silymarin combined with methylene blue photodynamic therapy against head and neck squamous cell carcinoma cells (HN5), with single, dual and triple treatment groups.

This study investigated the potential of nano-silymarin, a bioactive flavonolignan complex with known anticancer properties, in combination with methylene blue-mediated PDT (MB-PDT) in HNSCC cells.

Hefzi D et al., 2026-06-29: Iranian 2026 in-vitro study testing nano-silymarin combined with methylene blue photodynamic therapy against head and neck squamous cell carcinoma cells (HN5), with single, dual and triple treatment groups. C8 Iran (Tehran University of Medical Sciences). Study type: cell-line study (HN5), no patients. Groups: controls; nano-silymarin, methylene blue and laser alone; dual therapies; triple combination. Methylene blue concentration and light dose not in the abstract captured. Comparator: each monotherapy and control. Funder/conflicts: declarations present in the record; no competing interests stated in the captured text. Journal BMC Cancer 26(1). Bearing PARTLY: cell culture only, and the effect is of a three-part combination, not of methylene blue alone. Study type: lab.